<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717908</url>
  </required_header>
  <id_info>
    <org_study_id>KY1214</org_study_id>
    <nct_id>NCT04717908</nct_id>
  </id_info>
  <brief_title>Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS</brief_title>
  <acronym>TB-TRUSTplus</acronym>
  <official_title>Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (TB-TRUST)-PLUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety and tolerability of a combination&#xD;
      of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide treatments guided by PZA&#xD;
      sensitivity for 24 to 36 weeks in subjects with fluoroquinolone-resistant MDR-TB .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TB-TRUST-plus is a phaseIII, multicenter, open-label trial. The purpose of this study is&#xD;
      to assess the feasibility of the ultra-short treatment regimen guided by PZA sensitivity&#xD;
      among fluoroquinolone-resistant MDR-TB patients.A total of 200 participants with MDR-TB will&#xD;
      be recruited and followed up until 84 weeks after the treatment initiation.&#xD;
&#xD;
      This regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for&#xD;
      pyrazinamide drug sensitivity test), the regimen consists of bedaquiline, linezolid,&#xD;
      cycloserine, clofazimine and pyrazinamide. Then based on molecular PZA drug sensitivity&#xD;
      results, patients will be in divided into 3 sub-groups: pyrazinamide-susceptible (PZA-S)&#xD;
      patients , pyrazinamide-resistant (PZA-R) patients and pyrazinamide-unavailable&#xD;
      (PZA-U)patients.&#xD;
&#xD;
      The Regimen for PZA-S patients, consisting of bedaquiline, linezolid, cycloserine and&#xD;
      pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear&#xD;
      conversion by end of 16th and 20th week).&#xD;
&#xD;
      PZA-R sub-group regimen, consisting of bedaquiline, linezolid, cycloserine and clofazimine&#xD;
      ,are given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th&#xD;
      and 20th week) .&#xD;
&#xD;
      PZA-U sub-group continue the previous regimen, consisting of bedaquiline, linezolid,&#xD;
      cycloserine , clofazimine and pyrazinamide ,until 36th week (prolonged to 40 or 44 weeks if&#xD;
      no smear conversion by end of 16th and 20th week) .&#xD;
&#xD;
      The primary objective is to access the treatment success rate without relapse of the PZA&#xD;
      sensitivity guided ultra short regimen.&#xD;
&#xD;
      The secondary objective is to access the median time to sputum culture conversion. Safety&#xD;
      evaluations performed are the routine lab tests, blood glucose, vital signs,&#xD;
      electrocardiograph (ECG), reporting of adverse events, peripheral neuropathy brief examining&#xD;
      with the use of a Brief Peripheral Neuropathy rating scale(BPNS) and ophthalmologic&#xD;
      examination, including assessment of visual acuity and color vision，physical examinations and&#xD;
      chest CT. Adverse events will be monitored and promptly managed during the whole treatment&#xD;
      course.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success rate</measure>
    <time_frame>84 weeks after the treatment initiation</time_frame>
    <description>To access the treatment success rate without relapse .Treatment outcomes will be classified into favourable outcome and unfavourable outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The median time to Sputum Culture Conversion</measure>
    <time_frame>Time Frame: 12-36 weeks after treatment initiation</time_frame>
    <description>time from treatment initiation to the first of two consecutive negative sputum cultures without an intervening positive culture in liquid media</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of grade 3 or greater adverse events among patients</measure>
    <time_frame>84 weeks after treatment initiation</time_frame>
    <description>to access the proportion of patients who experience grade 3 or greater adverse events (graded according to the Division of AIDS severity criteria for adverse events) during treatment or follow-up;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multidrug Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>PZA sensitivity guided all oral regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide. Then based on molecular PZA drug sensitivity results, patients will be divided into three sub-groups.&#xD;
The regimen for PZA-S patients, consisting of bedaquiline, linezolid, cycloserine and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week).&#xD;
PZA-R sub-group regimen, consisting of bedaquiline, linezolid, cycloserine and clofazimine ,are given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) .&#xD;
PZA-U sub-group continue the previous regimen, consisting of bedaquiline, linezolid, cycloserine , clofazimine and pyrazinamide ,until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bedaquiline</intervention_name>
    <description>400 mg once daily for 2 weeks then 200mg 3 times per week;</description>
    <arm_group_label>PZA sensitivity guided all oral regimen</arm_group_label>
    <other_name>BDQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>1500 mg daily</description>
    <arm_group_label>PZA sensitivity guided all oral regimen</arm_group_label>
    <other_name>PZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>600 mg daily</description>
    <arm_group_label>PZA sensitivity guided all oral regimen</arm_group_label>
    <other_name>LZD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycloserine</intervention_name>
    <description>≤50kg 500 mg daily, &gt;50kg 750mg daily;</description>
    <arm_group_label>PZA sensitivity guided all oral regimen</arm_group_label>
    <other_name>Cs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
    <description>100 mg daily;</description>
    <arm_group_label>PZA sensitivity guided all oral regimen</arm_group_label>
    <other_name>CFZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in trial treatment and follow-up and can give informed consent&#xD;
&#xD;
          -  18-70 years old&#xD;
&#xD;
          -  Has smear-positive pulmonary tuberculosis with initial laboratory results with&#xD;
             resistance to rifampicin and isoniazide confirmed by GeneXpert&#xD;
&#xD;
          -  documented resistance to fluoroquinolones at screening&#xD;
&#xD;
          -  Can use bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide drugs&#xD;
             concerning the availability and costs of essential medicines&#xD;
&#xD;
          -  Willing to carry out HIV testing.&#xD;
&#xD;
          -  If the patient is a non-menopausal woman, agree to use or have used effective&#xD;
             contraception during treatment.&#xD;
&#xD;
          -  Have an identifiable address and stay in the area during the study period.&#xD;
&#xD;
          -  Willing to follow the follow-up study procedure after the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined extrapulmonary tuberculosis;&#xD;
&#xD;
          -  HIV antibody positive and AIDS patients;&#xD;
&#xD;
          -  Critically ill patients, and according to the judgment of the research physician, it&#xD;
             is impossible to survive for more than 16 weeks;&#xD;
&#xD;
          -  Known to be pregnant or breastfeeding;&#xD;
&#xD;
          -  Unable to attend or follow treatment or follow-up time;&#xD;
&#xD;
          -  Can not take oral medications;&#xD;
&#xD;
          -  Patients with impaired liver function (hepatic encephalopathy, ascites; total&#xD;
             bilirubin is more than 2 times higher than the upper limit of normal; ALT or AST is&#xD;
             more than 5 times the upper limit of normal);&#xD;
&#xD;
          -  Blood muscle spasm is more than 1.5 times the upper limit of normal;&#xD;
&#xD;
          -  The investigator believes that there are any social or medical conditions that expose&#xD;
             the subject to a safety hazard;&#xD;
&#xD;
          -  Simultaneously apply the drugs (glucocorticoids, interferons) that affect the efficacy&#xD;
             of this study; and apply the following drugs contraindicated with the study drug,&#xD;
             including non-steroidal anti-inflammatory drugs, monoamine oxidase inhibitors&#xD;
             (phenethyl hydrazine, different Carbofurs et al), direct or indirect sympathomimetic&#xD;
             drugs (such as pseudoephedrine), vasopressor drugs (such as adrenaline,&#xD;
             norepinephrine), dopamine drugs (such as dopamine, dobutamine), 5 a serotonin reuptake&#xD;
             inhibitor, a tricyclic antidepressant, a serotonin 5-HTI receptor antagonist&#xD;
             (amitriptyline), meperidine or buspirone.&#xD;
&#xD;
          -  Being allergic or intolerant of any study drug;&#xD;
&#xD;
          -  Currently participating in another drug clinical trial;&#xD;
&#xD;
          -  QTc interval ≥ 500 milliseconds during screening;&#xD;
&#xD;
          -  Hemoglobin is less than 90g/L or platelet is less than 75*10^9/L;&#xD;
&#xD;
          -  Have epilepsy, severe depression, irritability or psychosis；&#xD;
&#xD;
          -  Alcohol abuse（drinking more than 64g of ethanol a day for male, 42g for female）.&#xD;
&#xD;
          -  Subjects receive more than 2 weeks of bedaquiline, linezolid, cycloserine, clofazimine&#xD;
             or pyrazinamide 3 months prior to enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenhong Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Sun, Dr.</last_name>
    <phone>(086)15921403893</phone>
    <email>aaronsf1125@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Li, Dr.</last_name>
    <phone>(086)18817583793</phone>
    <email>y_li11@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third People's Hospital of Shenzhen City</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangzhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guofang Deng</last_name>
      <email>lalaliy@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guiyang Public Health Treatment Center</name>
      <address>
        <city>Guizhou</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongfeng Huang</last_name>
      <email>1017899870@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Zhengzhou</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Chen</last_name>
      <email>chenyuhnzz@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Chest Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liqiong Bai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huaihua first people's Hospital</name>
      <address>
        <city>Huaihua</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei Wang</last_name>
      <email>wp6598106@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial Tuberculosis Control Institute</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianhong Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chest Hospitalof Xinjiang Uygur Autonomous Region of PRC</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenlong Guan</last_name>
      <email>18999918582@189.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baoshan People's Hospital</name>
      <address>
        <city>Baoshan</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingying Xiao</last_name>
      <email>896939588@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan Provincial Infectious Disease Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yungui Zhang</last_name>
      <email>805903562@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hangzhou Red Cross Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingshan Cai</last_name>
      <email>caiqs66@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hwa Mei Hosptal,University of Chinese Academy of Sciences(Ningbo No.2 Hospital)</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yena Zhang</last_name>
      <email>408113485@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou Enze medical center Enze Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zebao He</last_name>
      <email>hezb@enzemed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Wenzhou City</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jichan Shi</last_name>
      <email>shijichan@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Chest Hospital</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqing Wu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Wen-hong Zhang</investigator_full_name>
    <investigator_title>Director of Division of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Multidrug resistant tuberculosis</keyword>
  <keyword>shorter treatment</keyword>
  <keyword>all-oral regimen</keyword>
  <keyword>PZA sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Bedaquiline</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

